HomeHealthcare and Life Sciences Europe Benign Prostatic Hyperplasia Treatment Market

Europe Benign Prostatic Hyperplasia Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacological treatmentAlpha-blockersTamsulosinSilodosinAlfuzosinDoxazosinOther alpha-blockers5-alpha reductase inhibitors (5-ARI)DutasterideFinasterideCombination therapyAlpha-blockers + 5-arisAlpha-blockers + pde5 inhibitorsPhosphodiesterase-5 inhibitors (pde5 inhibitors)Herbal and other drugs, Surgical treatmentTransurethral resection of the prostate (TURP)Transurethral incision of the prostate (TUIP)Open prostatectomyLaser therapyHolmium laser enucleation of the prostate (HOLEP)Photoselective vaporisation of the prostate (PVP), Minimally invasive proceduresUrolift systemRezūm water vapour therapyProstatic artery embolisationMicrowave thermotherapyTransurethral needle ablation (TUNA), Other treatmentsLifestyle modificationsWatchful waiting / active surveillance), By End Use (Hospitals, Clinics, Ambulatory surgical centres, Specialty urology centers), By Country (U.K., Germany, France, Spain, Italy, Russia, Nordic, Benelux) and Forecast, 2026-2034

Report Code: SMI3720PUB | Last Updated : 26 August, 2026 | Base Year : 2025 | Historical Data : 2022-2024 | Region : Europe | Format : PDF, Excel | Number of Pages : 140 | Author : Jenny Burkett

Table of Contents

  1. Executive Summary
    1. Introduction
  2. Market Introduction
    1. Market Definition
    2. Scope of the Study
    3. Market Structure
  3. Research Methodology
    1. Primary Research
    2. Research Methodology
    3. Assumptions & Exclusions
    4. Secondary Data Sources
  4. Market Factor Analysis
    1. Value Chain Analysis: Europe Benign Prostatic Hyperplasia Treatment Market
    2. Porters Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitution
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Dynamics
    1. Drivers
    2. Restraints
    3. Opportunities
  6. Recent Trends Analysis
  7. Impact of COVID-19 on Europe Benign Prostatic Hyperplasia Treatment Market
    1. Pre and Post Covid -19 Market Scenario Analysis
    2. Market Recovery Timeline and Challenge
    3. Measures Taken by Top Players
  8. Regulatory Landscape
  9. Europe Benign Prostatic Hyperplasia Treatment Market, By Type
    1. Introduction
      1. Market Size and Forecast, By Type
    2. Drugs
      1. Market Size and Forecast, By Region
    3. Devices
      1. Market Size and Forecast, By Region
    4. Surgery
      1. Market Size and Forecast, By Region
  10. Europe Benign Prostatic Hyperplasia Treatment Market, By Application
    1. Introduction
      1. Market Size and Forecast, By Application
    2. Monotherapy
      1. Market Size and Forecast, By Region
    3. Combination Therapy
      1. Market Size and Forecast, By Region
  11. Europe Benign Prostatic Hyperplasia Treatment Market, By Distribution Channel
    1. Introduction
      1. Market Size and Forecast, By Distribution Channel
    2. Hospital Pharmacies
      1. Market Size and Forecast, By Region
    3. Retail Pharmacies
      1. Market Size and Forecast, By Region
    4. Online Pharmacies
      1. Market Size and Forecast, By Region
  12. Regional Overview
    1. Introduction
      1. Market Size and Forecast
    2. Europe
      1. Market Size and Forecast
        1. By Type
          1. Drugs
            1. Devices
              1. Surgery
              2. By Application
                1. Monotherapy
                  1. Combination Therapy
                  2. By Distribution Channel
                    1. Hospital Pharmacies
                      1. Retail Pharmacies
                        1. Online Pharmacies
                      2. United Kingdom
                        1. By Type
                          1. Drugs
                            1. Devices
                              1. Surgery
                              2. By Application
                                1. Monotherapy
                                  1. Combination Therapy
                                  2. By Distribution Channel
                                    1. Hospital Pharmacies
                                      1. Retail Pharmacies
                                        1. Online Pharmacies
                                      2. Germany
                                      3. France
                                      4. Spain
                                      5. Italy
                                      6. Russia
                                      7. Nordic
                                      8. Benelux
                                      9. Rest of Europe
                                  3. Competitive Landscape, 2025
                                    1. Introduction
                                    2. Europe Benign Prostatic Hyperplasia Treatment Market Share Analysis, 2025 (%)
                                      1. Market Share Analysis, 2025
                                      2. Competition Ranking, 2025
                                      3. Key Developments & Growth Strategies
                                        1. Merger & Acquisition
                                        2. Product Launch
                                        3. Expansion
                                      4. Consolidated SWOT Analysis of Key Players
                                  4. Company Profile
                                    1. GlaxoSmithKline plc
                                      1. Business Overview
                                      2. Financial Data
                                      3. Key Product domains
                                      4. Recent Developments
                                    2. AstraZeneca plc
                                    3. Bayer AG
                                    4. Bristol-Myers Squibb Company
                                    5. Pfizer Inc.
                                    6. Sanofi S.A.
                                    7. Eli Lilly and Company
                                    8. Teva Pharmaceutical Industries Ltd.
                                    9. Boston Scientific Corporation
                                    10. Medtronic plc
                                    11. Olympus Corporation
                                    12. Karl Storz SE & Co. KG
                                    13. Procept BioRobotics Corporation
                                    14. NeoTract, Inc. (Teleflex Incorporated)
                                    15. Urologix, LLC